Stahl Alexander, Schachoff Sylvia, Beer Ambros, Winter Anna, Wester Hans Jürgen, Scheidhauer Klemens, Schwaiger Markus, Wolf Ingo
Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munich, Germany.
Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1328-36. doi: 10.1007/s00259-006-0078-6. Epub 2006 Apr 28.
During [(90)Y]DOTATOC therapy, for determination of kidney doses a conventional approach using co-injected [(111)In]DOTATOC was evaluated for validity, reliability and reproducibility as well as for the influence of methodological variations and bremsstrahlung. Biologically effective doses were estimated by calculating the relative effectiveness (RE) of kidney doses.
Fractionated [(90)Y]DOTATOC therapy (n=20 patients, 3.1+/-0.7 GBq/therapy cycle, 45 therapy cycles) included co-injection of 157+/-37 MBq [(111)In]DOTATOC and a nephroprotective infusion regimen. From serial gamma camera/probe measurements, individual region of interest (ROI) sets were established and kidney doses were determined according to MIRDOSE3 (corrected for individual kidney mass) by use of three methodological variants: (1) correction for interfering organs (liver/spleen) and background activity, (2) correction for interfering organs alone and (3) no corrections. A phantom study was performed with (111) In alone and with (111)In +(90)Y to estimate the influence of (90)Y bremsstrahlung.
Mean kidney dose (method 1, n=20 patients, 20 therapy cycles) was 1.51+/-0.60 Gy/GBq [(90)Y]DOTATOC (1.41+/-0.48 Gy/GBq for n=20 patients, 45 therapy cycles). With partial correction (method 2) or no correction (method 3) for interfering activity, kidney doses increased significantly, to 2.71+/-1.26 Gy/GBq and 3.15+/-1.22 Gy/GBq, respectively. The span of REs ranged from 1.02 to 1.24. Inter-observer variability was as high as +/-32% (+/-2SD). (90)Y bremsstrahlung accounted for a 4-11% underestimation of obtained target activity.
The obtained kidney doses are highly influenced by methodological variations. Full correction for interfering activity clearly underestimates kidney doses. By comparison, (90)Y bremsstrahlung and variability in the relative effectiveness of kidney doses cause minor bias. Inter-observer variability must be considered when interpreting kidney doses.
在[(90)Y]DOTATOC治疗期间,为了确定肾脏剂量,对使用共同注射的[(111)In]DOTATOC的传统方法进行了有效性、可靠性和可重复性评估,以及方法学变异和轫致辐射影响的评估。通过计算肾脏剂量的相对有效性(RE)来估计生物有效剂量。
分次[(90)Y]DOTATOC治疗(n = 20例患者,3.1±0.7 GBq/治疗周期,45个治疗周期)包括共同注射157±37 MBq[(111)In]DOTATOC和一种肾保护输注方案。根据连续的γ相机/探头测量,建立个体感兴趣区(ROI)集,并使用三种方法学变异根据MIRDOSE3(针对个体肾脏质量进行校正)确定肾脏剂量:(1)对干扰器官(肝脏/脾脏)和本底活性进行校正,(2)仅对干扰器官进行校正,(3)不进行校正。使用单独的(111)In以及(111)In +(90)Y进行了体模研究,以估计(90)Y轫致辐射的影响。
平均肾脏剂量(方法1,n = 20例患者,20个治疗周期)为1.51±0.60 Gy/GBq[(90)Y]DOTATOC(n = 20例患者,45个治疗周期时为1.41±0.48 Gy/GBq)。对于干扰活性进行部分校正(方法2)或不进行校正(方法3)时,肾脏剂量显著增加,分别达到2.71±1.26 Gy/GBq和3.15±1.22 Gy/GBq。RE的范围为1.02至1.24。观察者间的变异性高达±32%(±2SD)。(90)Y轫致辐射导致所获得的靶活性低估4 - 11%。
所获得的肾脏剂量受方法学变异的影响很大。对干扰活性进行完全校正明显低估了肾脏剂量。相比之下,(90)Y轫致辐射和肾脏剂量相对有效性的变异性导致的偏差较小。在解释肾脏剂量时必须考虑观察者间的变异性。